A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Treatment, Four 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 100mg, GSK2190915 300mg, Montelukast 10mg or Placebo Tablets Once Daily or Salmeterol 50mcg Inhalation Powder Twice Daily to Fluticasone Propionate 100mcg Inhalation Powder Twice Daily in Uncontrolled Asthmatic Subjects â‰¥ 12 Years of Age
Phase of Trial: Phase II
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Fiboflapon (Primary) ; Fluticasone propionate; Montelukast; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 13 Apr 2012 Actual patient number 160 added as reported by ClinicalTrials.gov.
- 13 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Aug 2011 Planned end date changed from 1 Jun 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.